In a report published Friday, Jefferies analyst Jeffrey Holford reiterated a Hold rating on Johnson & Johnson (NYSE: JNJ), and raised the price target from $91.00 to $92.00.
In the report, Jefferies noted, “Rising rate expectations had the expected impact on the sector, which has been driven by income investors over the past two years. Q2’13 earnings look tough in this context and we expect most companies to see some pressure. Novartis, Sanofi, Roche, Abbott, AbbVie and Bayer remain high conviction Buy ideas. We have downgraded Bristol-Myers and Pfizer to Hold in this report as part of our update today.” Johnson & Johnson closed on Thursday at $89.67.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. Tags: Jefferies, Jeffrey Holford
Posted in: Analyst Color, Price Target, Analyst Ratings